Paul William Manley

Summary

Affiliation: Novartis Institutes for BioMedical Research

Publications

  1. ncbi request reprint Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia
    Paul William Manley
    Novartis Institutes for BioMedical Research, WKL 136 4 86, CH 4002 Basel, Switzerland
    Biochim Biophys Acta 1754:3-13. 2005
  2. doi request reprint Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib
    Paul W Manley
    Novartis Institutes for BioMedical Research, Basel, Switzerland
    Bioorg Med Chem 18:6977-86. 2010
  3. ncbi request reprint Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis
    Paul William Manley
    Novartis Institutes of Biomedical Research, WKL 136 4 86, CH 4002 Basel, Switzerland
    Biochim Biophys Acta 1697:17-27. 2004

Detail Information

Publications3

  1. ncbi request reprint Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia
    Paul William Manley
    Novartis Institutes for BioMedical Research, WKL 136 4 86, CH 4002 Basel, Switzerland
    Biochim Biophys Acta 1754:3-13. 2005
    ..Recent advances with these and other promising classes of new CML drugs are reviewed...
  2. doi request reprint Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib
    Paul W Manley
    Novartis Institutes for BioMedical Research, Basel, Switzerland
    Bioorg Med Chem 18:6977-86. 2010
    ....
  3. ncbi request reprint Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis
    Paul William Manley
    Novartis Institutes of Biomedical Research, WKL 136 4 86, CH 4002 Basel, Switzerland
    Biochim Biophys Acta 1697:17-27. 2004
    ..This binding mode, similar to that observed for the anti-leukemia drug, imatinib in complex with c-Abl kinase, may be responsible for the high selectivity of AAL993 and provides valuable insight for the design of further compounds...